[Anti-IGE therapy in asthma].
Immunoglobulin E (IgE) is the hallmark of allergic diseases and asthma. Regulating IgE production has been the focus over several years as an important strategy in the treatment of allergic diseases. Recently, nonanaphylactogenic antihuman IgE antibodies have been under clinical evaluation as a therapeutic agent against atopic disease. In asthmatic subjects, the administration of these monoclonal anti-IgE antibody has been shown to reduce plasma IgE levels, reduce early and late phase allergic responses after allergen provocation, improve symptoms and reduce rescue medication. No serious side effects were reported. Thus, the clinical effectiveness of these medications supports the viability of anti-IgE therapy as a potentially effective treatment option for asthma.
Mehiri Ben Rhouma
Nadia
N
Service Pneumo-Allergologie, Hôpital La Rabta Tunis.
Béji
Majed
M
Louzir
Béchir
B
Daghfous
Jalloul
J
D000485:Allergens / Q000276:immunology*; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy; D007073:Immunoglobulin E / Q000276:immunology*; D051379:Mice; D010919:Placebos; D011817:Rabbits; D017455:Receptors, IgE / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000276:immunology; D013997:Time Factors
D000485:Allergens; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; C110070:CGP 51901; D010919:Placebos; D017455:Receptors, IgE; C026408:anti-IgE antibodies; C401983:rhuMAb-E25; D007073:Immunoglobulin E